Roche remains bullish on giredestrant despite first-line trial setback

Roche's CEO Thomas Schinecker said the company still expects its investigational oral breast cancer therapy giredestrant to generate strong sales, potentially surpassing Herceptin.

The optimism follows giredestrant's failure to meet its primary endpoint in a first-line trial earlier this year, a setback that limits its immediate regulatory prospects.

Roche believes the drug’s mechanism and market positioning could capture a sizable share of the HER2-positive breast cancer market, where Herceptin remains dominant.

The company has not disclosed revised timelines or revenue forecasts, but the comments indicate it will continue development and explore later-line indications.